Showing results (1221-1230 of 2,755) with videos related to

Sort By:
Pageof 276
Pharmacogenomics|October 1, 2015
High-throughput screening identified inherited genetic variations in the EGFR pathway contributing to skin toxicity of EGFR inhibitorsSayed-Mohammad Hasheminasab, Mladen V Tzvetkov, Christian Schumann, et al.
Pharmacogenomics|October 1, 2015
Population pharmacokinetics and pharmacodynamics of busulfan with GSTA1 polymorphisms in patients undergoing allogeneic hematopoietic stem cell transplantationBoyoon Choi, Myeong Gyu Kim, Nayoung Han, et al.
Pharmacogenomics|August 29, 2015
Association between PK/PD-involved gene polymorphisms and carbamazepine-individualized therapyChun-Lai Ma, Zheng Jiao, Xun-Yi Wu, et al.
Pharmacogenomics|August 11, 2015
Identification and characterization of a novel CYP2C9 allelic variant in a warfarin-sensitive patientDa-Peng Dai, Chuan-Bao Li, Shuang-Hu Wang, et al.
Pharmacogenomics|August 13, 2015
Polymorphisms in SLCO1B3 and NR1I2 as genetic determinants of hematotoxicity of carboplatin and paclitaxel combinationLitaty Céphanoée Mbatchi, Antonin Schmitt, Fabienne Thomas, et al.
Pharmacogenomics|August 1, 2015
Genetic variants in SLC22A17 and SLC22A7 are associated with anthracycline-induced cardiotoxicity in childrenHenk Visscher, S Rod Rassekh, George S Sandor, et al.
Pharmacogenomics|December 11, 2014
Pharmacogenetics of cardiac inotropyAnastasios Lymperopoulos, Dilayda Garcia, Karlee Walklett
Pharmacogenomics|December 11, 2014
Pharmacogenetics of SULT1A1Jaclyn Daniels, Susan Kadlubar
Pharmacogenomics|December 16, 2014
SNPs and taxane toxicity in breast cancer patientsVirginia Bosó, María José Herrero, Ana Santaballa, et al.
Pharmacogenomics|December 16, 2014
Evaluation of the relationship between polymorphisms in CYP2C19 and the pharmacokinetics of omeprazole, pantoprazole and rabeprazoleManuel Román, Dolores Ochoa, Sergio Daniel Sánchez-Rojas, et al.
Pageof 276